Medically reviewed by Puja Vyas, Lead Clinical Pharmacist.
If you are considering a clinician-led weight management programme and you are also thinking about starting a family, fertility is a reasonable thing to want clarity on before you begin. This article covers what the current published evidence actually shows about how Mounjaro (tirzepatide) may interact with male reproductive health, where the gaps in that evidence sit, and what to raise with a clinician before starting.
What We Know About Tirzepatide and Male Fertility
The honest answer, as of 2026, is that direct human evidence on this question is limited. The large clinical trials that established the efficacy and safety profile of tirzepatide were not designed to measure fertility outcomes as primary endpoints. Most of the reproductive safety data available comes from animal studies, and applying those findings to men requires real caution.
In the animal reproductive studies submitted for tirzepatide's licensing, no effects on male fertility were observed - sperm morphology, mating, fertility and conception were all unaffected in male rats, including at exposures above the maximum recommended human dose. The reproductive findings that were seen occurred in female rats (altered oestrous cycling and fewer implantation sites) and in pregnant animals during organogenesis, and were attributed to the drug's effects on food intake and body weight rather than a direct effect on reproduction. There is no signal in this data pointing to a male fertility risk at clinical doses.
No large, peer-reviewed human study has shown that tirzepatide causes male infertility. That absence of evidence is not the same as evidence of safety - it reflects how recently this treatment arrived, not a confirmed reassurance.
How Obesity Itself Affects Male Fertility
Before looking at what the treatment may or may not do, it is worth understanding what excess weight does to male reproductive health on its own. The evidence here is considerably stronger.
Obesity is associated with lower testosterone, higher oestrogen levels (because adipose tissue converts androgens to oestrogens), reduced sperm motility, lower sperm concentration, and increased DNA fragmentation in sperm. A 2013 systematic review published in Human Reproduction Update found an association between higher BMI and abnormal sperm count, including higher rates of oligozoospermia and azoospermia, compared with men of healthy weight.
Elevated body weight also raises scrotal temperature, which matters because sperm production is temperature-sensitive. Metabolic conditions that tend to accompany obesity - insulin resistance and elevated blood glucose among them - have been independently linked to impaired sperm quality.
This context is important. Any honest assessment of how a weight management treatment affects fertility has to account for the baseline. For many men, the metabolic improvements that come with meaningful, supervised weight loss may actually benefit reproductive health rather than harm it.
What Happens to Testosterone During Weight Loss Treatment
One of the more consistent findings across weight-loss research is an improvement in testosterone levels in men who lose significant body weight. A 2010 study published in Diabetes Care found that testosterone concentrations were substantially lower in obese men, consistent with the known mechanism by which excess fat suppresses androgen levels. Subsequent research has shown that weight loss — through various methods — tends to reverse this effect. We look at how this plays out with different GLP-1 treatments in our Wegovy vs Mounjaro comparison for men.
This is not a direct fertility measure, but testosterone is central to sperm production, and improvements in testosterone in men with low baseline levels are generally considered a positive signal for reproductive function.
The mechanism is well established: as visceral fat decreases, peripheral conversion of androgens to oestrogens falls, and the hypothalamic-pituitary-gonadal axis - which regulates testosterone production - functions more effectively. This effect is not unique to any one treatment; it follows meaningful weight loss by most supervised routes.
The Evidence Gap: What Has Not Been Studied
The major clinical trials for tirzepatide enrolled participants to measure weight loss and cardiometabolic outcomes. Semen analysis, sperm DNA integrity, and time-to-conception were not endpoints in those trials.
That means there is no robust human data confirming the treatment has no effect on sperm parameters - and equally no robust data confirming that it does. The regulatory prescribing information notes that caution is warranted in patients planning to conceive, and that contraception is recommended during treatment for women. The guidance for men is less specific, which itself reflects the evidence gap rather than a clean bill of health.
If fertility is a near-term priority, that conversation needs to happen with a clinician before you start, not after.
Does the Pace of Weight Loss Matter?
Some men ask whether the speed of weight loss, rather than the treatment itself, could affect fertility. Rapid weight loss through any method - including very low calorie diets - has been associated with short-term hormonal disruption. The hypothalamic-pituitary-gonadal axis is sensitive to significant caloric restriction, and in extreme cases this can temporarily suppress testosterone production.
In clinical trials of tirzepatide, weight loss is gradual and dose-escalated over months. The titration approach used in structured programmes is designed to avoid the kind of acute physiological stress associated with crash dieting. Whether this paced approach eliminates any transient hormonal disruption is not something the current literature can confirm with certainty - but the contrast with extreme restriction is worth noting.
What to Do If You Are Planning to Start a Family
If you are actively trying to conceive, or planning to within the next twelve months, discuss this directly with a prescribing clinician before starting any weight management programme. That conversation should cover your current reproductive health, your timeline, and whether the potential metabolic benefits of weight loss outweigh any theoretical risks during treatment.
For men who are not actively trying to conceive but want a clearer picture of their metabolic health, a structured programme that monitors key biomarkers provides useful information. Every HeMed programme includes an at-home no-needle blood test monitoring 10 health biomarkers as standard - cholesterol, HbA1c, liver function, thyroid, glucose, and others. This panel does not include semen analysis, but it gives a clear view of the metabolic factors known to affect male reproductive health. You can read more about how the HeMed programme works.
When to See a GP
Speak with your GP if:
- You have been trying to conceive for twelve months or more without success
- You have a known hormonal condition such as hypogonadism or hyperprolactinaemia
- You have previously had fertility investigations that identified a problem
- You are taking other medications that may interact with reproductive hormones
A clinician-led weight management programme is not a substitute for specialist fertility assessment. If you have active fertility concerns, a referral to a urologist or reproductive medicine specialist is the right step.
The Broader Picture: Metabolic Health and Male Reproductive Function
The strongest evidence-based intervention for improving male fertility in men with obesity remains weight loss itself. Lower body weight reduces oestrogen excess, improves testosterone, reduces insulin resistance, and lowers scrotal temperature. A 2011 study in Reproductive Health found that weight loss was associated with measurable improvements in semen parameters and reproductive hormones in obese men.
For men considering a clinician-led programme, the question is not simply whether the treatment affects fertility in isolation. It is what the net effect of meaningful, supervised weight loss is likely to be on their overall metabolic and reproductive health. For most men with a BMI above 30, the evidence points toward benefit.
If you want to understand what a structured programme looks like in practice, our Mounjaro for men overview sets out how the treatment pathway works and what the clinical process involves before any prescription is issued.
Frequently Asked Questions
Does Mounjaro affect male fertility?
The current human evidence is limited - the large weight-loss trials were not designed to measure fertility outcomes in men. In the animal studies used for licensing, no effect on male fertility was seen; the reproductive findings occurred in female and pregnant animals and were linked to reduced food intake and body weight. If fertility is a near-term concern, raise it with a clinician before starting.
Can weight loss treatment improve testosterone levels in men?
Clinical data suggests that significant weight loss is associated with improvements in testosterone in men with obesity. This is consistent with the known mechanism by which excess body fat suppresses testosterone through increased conversion of androgens to oestrogens.
Should I stop treatment if I am trying to conceive?
This is a question for your prescribing clinician. There is no evidence that the treatment causes male infertility, but there is also limited data confirming it has no effect. A clinician can help you weigh your individual circumstances and timeline.
Does obesity affect male fertility independently of any treatment?
Yes. Obesity is independently associated with lower testosterone, reduced sperm motility, lower sperm concentration, and increased sperm DNA fragmentation. For many men, the metabolic improvements from supervised weight loss may benefit reproductive health.
What biomarkers does HeMed monitor during treatment?
Every HeMed programme includes an at-home no-needle blood test monitoring 10 health biomarkers as standard, including cholesterol, HbA1c, liver function, thyroid, and glucose. This gives ongoing visibility of the metabolic factors most relevant to men's health throughout treatment.
Is there a fertility test included in the HeMed programme?
No. The HeMed blood test panel monitors metabolic biomarkers, not semen parameters. If you have specific fertility concerns, a GP referral to a reproductive medicine specialist is the appropriate route.
When should I see a GP about fertility before starting a weight management programme?
Speak with your GP if you have been trying to conceive for twelve months or more without success, have a known hormonal condition, have had previous fertility investigations, or are taking medications that may affect reproductive hormones.
References
- Sermondade N, et al. BMI in relation to sperm count: an updated systematic review and collaborative meta-analysis. Human Reproduction Update. 2013;19(3):221-231.
- Katib A. Mechanisms linking obesity to male infertility. Central European Journal of Urology. 2015;68(1):79-85.
- Lotti F, Maggi M. Sexual dysfunction and male infertility. Nature Reviews Urology. 2018;15(5):287-307.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216.
- Dhindsa S, et al. Testosterone concentrations in diabetic and nondiabetic obese men. Diabetes Care. 2010;33(6):1186-1192.
- Hakonsen LB, et al. Does weight loss improve semen quality and reproductive hormones? Results from a cohort of severely obese men. Reproductive Health. 2011;8:24.
HeMed’s personalised weight loss programme uses medical treatment to help you achieve results that last.
